62 related articles for article (PubMed ID: 24128110)
1. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
Curik N; Laznicka A; Polivkova V; Krizkova J; Pokorna E; Semerak P; Suchankova P; Burda P; Hochhaus A; Machova Polakova K
Leukemia; 2024 Jun; 38(6):1415-1418. PubMed ID: 38615117
[No Abstract] [Full Text] [Related]
2. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
Sanford D; Kantarjian H; Skinner J; Jabbour E; Cortes J
Haematologica; 2015 Dec; 100(12):e494-5. PubMed ID: 26341741
[No Abstract] [Full Text] [Related]
3. BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.
Byrgazov K; Lucini CB; Valent P; Hantschel O; Lion T
Haematologica; 2018 Jan; 103(1):e10-e12. PubMed ID: 28983061
[No Abstract] [Full Text] [Related]
4. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
Boucher L; Rozalska L; Sorel N; Olivier G; Hernanz MPG; Cayssials E; Raimbault A; Chomel JC
Leuk Res; 2024 Feb; 137():107439. PubMed ID: 38281466
[No Abstract] [Full Text] [Related]
5. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.
Eiring AM; Deininger MW
Genome Biol; 2014 Sep; 15(9):461. PubMed ID: 25316524
[TBL] [Abstract][Full Text] [Related]
6. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.
Saussele S; La Rosée P; Kiani A; Haverkamp W; Jentsch-Ullrich K; Stegelmann F; Rieger C; Waller CF; Franke GN; Junghanss C; Kirchmair R; Theurl M; le Coutre P
Acta Haematol; 2024; 147(3):344-351. PubMed ID: 37848002
[TBL] [Abstract][Full Text] [Related]
7. Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
Okabe S; Moriyama M; Gotoh A
Leuk Lymphoma; 2024 May; 65(5):696-699. PubMed ID: 38300854
[No Abstract] [Full Text] [Related]
8. Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
Iurlo A; Cattaneo D; Malato A; Accurso V; Annunziata M; Gozzini A; Scortechini AR; Bucelli C; Scalzulli E; Attolico I; Maggi A; Martino B; Caocci G; Abruzzese E; Pregno P; Luciano L; Breccia M
Am J Hematol; 2020 Oct; 95(10):E260-E263. PubMed ID: 32557788
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.
Breccia M; Abruzzese E; Iurlo A; Gozzini A; Isidori A; Gangemi D; Pregno P; Alimena G
Haematologica; 2016 Jun; 101(6):e267-8. PubMed ID: 27252515
[No Abstract] [Full Text] [Related]
10. Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
Rea D
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):243-247. PubMed ID: 33275744
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib: A comprehensive drug profile.
Attwa MW; Alkahtani HM; El-Azab AS; Abdel-Aziz AA; Abdelhameed AS; Kadi AA; Hassan SB; Zeidan DW; Bakheit AH
Profiles Drug Subst Excip Relat Methodol; 2024; 49():81-114. PubMed ID: 38423710
[TBL] [Abstract][Full Text] [Related]
12. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Hornak T; Mayer J; Cicatkova P; Semerad L; Kvetkova A; Klamova H; Faber E; Belohlavkova P; Karas M; Stejskal L; Cmunt E; Cerna O; Srbova D; Zizkova H; Vrablova L; Skoumalova I; Voglova J; Jurkova T; Chrapava M; Jurcek T; Jeziskova I; Jarosova M; Machova Polakova K; Papajik T; Zak P; Jindra P; Zackova D
Am J Hematol; 2024 Apr; 99(4):763-766. PubMed ID: 38317312
[TBL] [Abstract][Full Text] [Related]
13. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Bagadi S; Saikia T; Pany A; Das B
Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
[TBL] [Abstract][Full Text] [Related]
14. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
15. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
17. [Management of advanced stage chronic myeloid leukemia].
Takahashi N
Rinsho Ketsueki; 2014 Oct; 55(10):1860-9. PubMed ID: 25297750
[No Abstract] [Full Text] [Related]
18. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
